DBV Technologies S.A. (NASDAQ:DBVT) was downgraded by research analysts at Morgan Stanley from an “overweight” rating to an “equal weight” rating in a research note issued to investors on Monday, Marketbeat Ratings reports.

Other equities analysts have also issued research reports about the stock. Deutsche Bank AG raised their price objective on shares of DBV Technologies from $46.00 to $56.00 in a research report on Sunday, October 8th. Jefferies Group LLC reaffirmed a “buy” rating on shares of DBV Technologies in a research report on Thursday, August 31st. Zacks Investment Research raised shares of DBV Technologies from a “hold” rating to a “buy” rating and set a $50.00 price objective on the stock in a research report on Tuesday, August 29th. BidaskClub raised shares of DBV Technologies from a “hold” rating to a “buy” rating in a research report on Tuesday, August 22nd. Finally, HC Wainwright reissued a “buy” rating and issued a $50.00 price target on shares of DBV Technologies in a research report on Thursday, July 6th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company. DBV Technologies presently has a consensus rating of “Buy” and a consensus price target of $54.71.

DBV Technologies (DBVT) traded down 42.65% during midday trading on Monday, hitting $27.57. 9,897,773 shares of the stock traded hands. DBV Technologies has a 1-year low of $22.33 and a 1-year high of $50.57. The company has a 50-day moving average price of $44.94 and a 200-day moving average price of $39.47. The firm’s market cap is $1.27 billion.

COPYRIGHT VIOLATION NOTICE: This report was posted by American Banking News and is the property of of American Banking News. If you are reading this report on another publication, it was illegally stolen and republished in violation of US and international trademark & copyright law. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/10/23/dbv-technologies-s-a-dbvt-downgraded-to-equal-weight-at-morgan-stanley.html.

Large investors have recently made changes to their positions in the business. Point72 Asset Management L.P. bought a new stake in DBV Technologies during the 1st quarter worth about $1,120,000. Janus Henderson Group PLC bought a new stake in DBV Technologies during the 2nd quarter worth about $90,724,000. Bank of America Corp DE raised its holdings in DBV Technologies by 86.3% during the 1st quarter. Bank of America Corp DE now owns 26,574 shares of the company’s stock worth $936,000 after purchasing an additional 12,309 shares during the last quarter. Morgan Stanley raised its holdings in DBV Technologies by 89.9% during the 1st quarter. Morgan Stanley now owns 249,988 shares of the company’s stock worth $8,805,000 after purchasing an additional 118,317 shares during the last quarter. Finally, Jane Street Group LLC bought a new stake in DBV Technologies during the 1st quarter worth about $853,000. 45.52% of the stock is owned by hedge funds and other institutional investors.

About DBV Technologies

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.

Analyst Recommendations for DBV Technologies (NASDAQ:DBVT)

Receive News & Ratings for DBV Technologies S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies S.A. and related companies with MarketBeat.com's FREE daily email newsletter.